“We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5×30 strategic priorities, leaving us well-positioned for sustainable, long-term success,” said Frank Lee, chief executive officer of Pacira (PCRX) BioSciences. “Strong Exparel volume growth in the second half of the year underscores the value of our commercial investments and positions us for significant and sustainable revenues moving forward. We enter 2026 with momentum that provides us with a strong foundation and clear line of sight to further operational progress and an exciting chapter of growth ahead.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- DOMA intends to nominate three director candidates at Pacira annual meeting
- Pacira Ends Hip Osteoarthritis Injection Study for ZILRETTA: What Investors Should Know
- Pacira joins PROBE Consortium
- Pacira initiated with an Equal Weight at Barclays
- Pacira reports inducement grants under Nasdaq listing rule